• Global drug spending to hit $1.4 trillion in 2020: IMS

    Global spending on medicines will reach $1.4 trillion in 2020, driven by increased healthcare access in emerging markets and high-priced new drugs for cancer and other diseases, according to a forecast by IMS Health released on Wednesday. That is up from about $1.07 trillion this year, representing a compound annual growth rate of 4 to 7 percent over the next five years, the "Global Medicines Use in 2020" report compiled by IMS Institute for Healthcare Informatics found. Some 225 new drugs will

  • Lessons from Australia and China’s Healthcare Cooperation: What Can Canadian Firms Learn?

    NAI500 Comments: i. The Chinese government is heavily focused on the health of its citizens as shown by its decision to build 7,500 public hospitals through the private sector over the next decade. ii. China’s health challenges include significantly high rates of smoking, high pollution levels, and a rapidly aging population. iii. Given China’s healthcare challenges, Canadian healthcare developers should target cancer treatment, heart disease treatment, and age related solutions. iv. The cit

  • South Korea's Genexine expands into China in Tasgen deal for up to $100M

    South Korean biotech Genexine Inc. licensed out three of its compounds for $100 million to a Chinese drug developer, exploring the Asian market for next-generation long-acting growth hormone treatments. Clinical-stage Genexine (KOSDAQ:095700) signed a licensing and technology transfer agreement with China's Tasgen, a subsidiary of Tasly Pharmaceutical Group Co. Ltd. (SH:600535). Under the deal reached this week, Genexine will grant the China rights for three compounds, GX-H9, GX-G6 and GX-G3, to Tasgen i

Investment Opportunities


Potash in another mining friendly region other than Saskatchewan

With the junior mining sector struggling in the past few years, it is difficult for inv... Full Story

The hidden gems in CSE

Breaking News

BGI's $250 Million Shenzhen IPO Scheduled for July

BGI, a Shenzhen genomics company, is edging closer to an IPO. The company now expects to raise $250 million on Shenzhen's Chi-Next Exchange sometime in July, following all-but-fin...

Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL 453 in China

San Francisco's Sinovas Starts $75 Million China VC Fund

IBM grows Baheal deal to bring Watson genomics to China

Shanghai ChemPartner Plans Reverse Merger with China's Quantum

Select Companies

Naturally Splendid Enterprises Ltd

Naturally Splendid is a multifaceted biotechnology company that is developing, producing, commerc...

CohBar, Inc.

CohBar is an innovator and leader in the research and development of mitochondria-based therapeut...

Diamedica Inc

Diamedica Inc is a development stage biopharmaceutical company. The Company is engaged in the dis...

Experts Column

Top 10 Developments that Investors should pay extra attention in the new year

Gilber Chan, the President of NAI500, presents the latest speech of 2016 investment strategy on Global Chinese Financial Forum - Vancouver Conference 2016: The Top 10 Developments...

China could boost growth with supply, property reforms, tax cuts, HSBC says

China's policymakers still have ammunition to counter the mainland's slowing economy, including supply-side reforms and subsidized housing, HSBC said. In a note released Tu...

Here’s how to play Chinese stocks in 2016?

Consumer staples and services, health care, software and auto stocks are Henderson Global Investors' top Chinese stock picks for 2016 — but don't get your hopes up for a...

G-20 sticks to 2% growth goal despite headwinds

The leaders of the world's largest economies stuck to a goal of lifting their collective output by an extra 2 percent by 2018, even though growth remains uneven and weaker than expect...

Why isn't the yuan rising despite IMF support?

The renminbi's status as a global reserve currency may be effectively guaranteed following formal backing by International Monetary Fund (IMF) staff, according to economists, but trad...

Press Release


  Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company” or “Lexaria”) announces the filing of a new provisional patent application and stock and o...

DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

, a biopharmaceutical company focused on the development of new cancer therapies, today announced it has received Institutional Review Board (IRB) approval to conduct its pivotal Phase 3 ...

Resverlogix Closes $10 Million of Equity Subscriptions

today closed its previously-announced offering, issuing a total of $10 million of its equity units. Eastern Capital Limited ("Eastern") and Shenzhen Hepalink Pharma...

DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma ("GBM") at SNO's Pediatric Neuro-Oncology Basic and Translational Research Conference

RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA™) for H. pylori Infection

RedHill Biopharma Initiates Promotion of Donnatal® and EnteraGam® in the U.S

RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis

RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map

Resverlogix to Raise Up To $10 Million

Top Hits News

Daily Top Performing Life Science Stocks
         Company Name Symbol Price Change Vol(k) Day's Range Contact
1 AVEO Pharmaceuticals Inc NASDAQ:AVEO 1.250
0.520 (71.75%)
54841423 1.05 - 1.38
2 Kane Biotech Inc. TSXV:KNE 0.125
0.020 (19.05%)
58000 0.115 - 0.125
3 Oragenics Inc NYSE MKT:OGEN 0.416
0.056 (15.44%)
31267 0.3780 - 0.4583
4 Retractable Technologies Inc NYSE MKT:RVP 1.150
0.080 (7.48%)
83868 1.07 - 1.15
5 Sunesis Pharmaceuticals Inc NASDAQ:SNSS 3.190
0.220 (7.41%)
2103917 2.85 - 3.20
6 MEI Pharma Inc NASDAQ:MEIP 2.300
0.140 (6.48%)
635908 2.14 - 2.30
7 Apricus Biosciences Inc NASDAQ:APRI 1.160
0.070 (6.42%)
1981895 1.08 - 1.27
8 Biodel Inc NASDAQ:BIOD 0.650
0.030 (5.51%)
0 N/A
9 Vermillion Inc NASDAQ:VRML 1.930
0.100 (5.46%)
38813 1.81 - 1.93
10 GTx Inc NASDAQ:GTXI 4.810
0.230 (5.02%)
125087 4.42 - 4.89
11 Esperion Therapeutics Inc NASDAQ:ESPR 44.340
2.030 (4.80%)
764853 41.42 - 44.54
12 Enzo Biochem Inc NYSE:ENZ 11.540
0.520 (4.72%)
723722 10.85 - 11.61
13 Rexahn Pharmaceuticals Inc NYSE MKT:RNN 3.150
0.140 (4.65%)
235829 2.99 - 3.17
14 Centric Health Corp TSX:CHH 0.730
0.030 (4.29%)
278200 0.70 - 0.74
15 Pernix Therapeutics Holdings Inc NASDAQ:PTX 4.620
0.170 (3.82%)
184124 4.37 - 4.69